Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and ExpositionPRNewsWire • 12/07/25
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/05/25
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 11/27/25
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyPRNewsWire • 11/17/25
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong BuyZacks Investment Research • 11/06/25
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/25
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and ExpositionPRNewsWire • 11/03/25
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'CNBC • 10/30/25
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business UpdatePRNewsWire • 10/29/25
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?Zacks Investment Research • 10/15/25